Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today announced that its presentation at the Morgan Stanley Global Healthcare Conference will be webcast and may be accessed at www.sucampo.com.
Members of Sucampo Pharmaceuticals’ senior management team will participate in this session on Tuesday, September 15, 2009, starting at 10:55 am Eastern Time.
Investors interested in listening to the live webcast should log on before the start time in order to download any software required. The archive of the webcast will be available for several days after the live event.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc.,
an international biopharmaceutical company based in Bethesda, Maryland,
focuses on the development and commercialization of medicines based on
prostones. The therapeutic potential of prostones, which are bio-lipids
that occur naturally in the human body, was first identified by Ryuji
Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals’ Chairman and Chief
Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with
Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently
Advisor, International Business Development.
Sucampo markets AMITIZA® (lubiprostone) 24 mcg in the U.S. for chronic idiopathic constipation in adults and Amitiza 8 mcg in the U.S. to treat irritable bowel syndrome with constipation in adult women. Sucampo also is developing the drug for additional gastrointestinal disorders with large potential markets. In April 2009, Sucampo acquired U.S. and Canadian rights to Rescula®, an FDA-approved treatment for open-angle glaucoma and ocular hypertension. Sucampo plans to re-launch Rescula in 2010, and to develop it for additional ophthalmic indications. In addition, Sucampo has a robust pipeline of compounds with the potential to target underserved diseases affecting millions of patients worldwide.
Sucampo Pharmaceuticals, Inc. has three wholly owned subsidiaries: Sucampo Pharma Europe, Ltd., located in the UK; Sucampo Pharma, Ltd., located in Japan; and Sucampo Pharma Americas, Inc., located in Maryland. To learn more about Sucampo Pharmaceuticals and its products, visit www.sucampo.com.
Amitiza is a registered trademark of Sucampo Pharmaceuticals, Inc. and Rescula is a registered trademark used under license.
Forward-Looking Statements
Any statements in this press
release about future expectations, plans and prospects for Sucampo
Pharmaceuticals are forward-looking statements made under the provisions
of The Private Securities Litigation Reform Act of 1995. Forward-looking
statements may be identified by the words “project,” “believe,”
“anticipate,” “plan,” “expect,” “estimate,” “intend,” “should,” “would,”
“could,” “will,” “may” or other similar expressions. Forward-looking
statements include statements about the potential utility of Amitiza and
Rescula to treat particular indications and expected trial commencement,
regulatory and launch dates. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including those described in Sucampo
Pharmaceuticals’ filings with the Securities and Exchange Commission
(SEC), including the annual report on Form 10-K for the year ended
December 31, 2008 and other periodic reports filed with the SEC. Any
forward-looking statements in this press release represent Sucampo
Pharmaceuticals’ views only as of the date of this release and should
not be relied upon as representing its views as of any subsequent date.
Sucampo Pharmaceuticals does not undertake any obligation to update any
forward-looking statements contained in this release as a result of new
information, future events or otherwise, except as required by law.
Contacts:
Sucampo Pharmaceuticals, Inc.
Kate de Santis, 240-223-3834
